Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Mol Cell Biochem ; 224(1-2): 19-27, 2001 Aug.
Article in English | MEDLINE | ID: mdl-11693196

ABSTRACT

The present study was undertaken to determine the effects of AT1 receptor blockade which occurred in response to losartan, on the extracellular matrix (ECM) degradation process in the Bio 14.6 (n = 12) and Bio 53.58 (n = 12) strains which are referred as models of hypertrophic and dilated cardiomyopathy, respectively. The administration of losartan (30 mg/kg/day) in hamsters from 10-20 weeks of age reduced the accumulation of the left ventricular collagen matrix in both of the Bio 14.6 and the Bio 53.58 strains. According to the RT-PCR, the levels of mRNA for matrix metalloproteinase (MMP) and the tissue inhibitor of MMP (TIMP) were examined. MMP-1, -2, -3, and -9 were more enhanced in both myopathic strains than in the control F1beta, strains. With losartan, the levels of MMP-1, -2, -9, TIMP-1 and -2 decreased in the both strains but those for MMP-3 did not in Bio 14.6 strains. TIMP-3 and -4 mRNA levels did not change in any of the experimental hamsters, whether treated or untreated with losartan. The Western blots also showed similar observations in the both strains as seen in mRNA expressions although MMP-2 in the Bio 53.58 strains did not differ between treated and untreated with losartan. Although losartan has an inhibitory effect on collagen accumulation in the development of cardiomyopathy, MMPs (-1, -2, -9) and TIMPs (-1, -2) seem to be susceptible to responding to losartan in Bio cardiomyopathic hamsters.


Subject(s)
Cardiomyopathy, Dilated/enzymology , Cardiomyopathy, Hypertrophic/enzymology , Collagen/metabolism , Losartan/pharmacology , Angiotensin Receptor Antagonists , Animals , Blotting, Western , Body Weight/drug effects , Cardiomyopathy, Dilated/genetics , Cardiomyopathy, Dilated/metabolism , Cardiomyopathy, Dilated/pathology , Cardiomyopathy, Hypertrophic/genetics , Cardiomyopathy, Hypertrophic/metabolism , Cardiomyopathy, Hypertrophic/pathology , Cricetinae , Gene Expression Regulation, Enzymologic/drug effects , Kinetics , Male , Matrix Metalloproteinases/genetics , Matrix Metalloproteinases/metabolism , Myocardium/enzymology , Myocardium/metabolism , Myocardium/pathology , Organ Size/drug effects , RNA, Messenger/genetics , RNA, Messenger/metabolism , Receptors, Angiotensin/metabolism , Reverse Transcriptase Polymerase Chain Reaction , Tissue Inhibitor of Metalloproteinases/metabolism
2.
J Mol Cell Cardiol ; 31(9): 1607-15, 1999 Sep.
Article in English | MEDLINE | ID: mdl-10471345

ABSTRACT

The myocardium contains a collagen matrix composed primarily of collagen and fibronectin, which are major determinants of the myocardial architecture, structural integrity and mechanical properties. The present study was undertaken to determine the age-related changes of the accumulation and degradation of the collagen matrix in Syrian myopathic hamsters, of the Bio 14.6 and Bio 53.58 strains. Those hamsters were used as models for hypertrophic and dilated cardiomyopathy, respectively. The heart to body weight ratio in the Bio 14.6 strains was higher (P<0.05) than that in the age-matched F1b strains. In the Bio 53.58 strains, the heart to body weight ratio was higher at 8 and 42 weeks of age than that in the F1b strains. The collagen content increased from 22 weeks of age in both Bio hamsters compared with age-matched F1b hamsters (P<0.05). In both cardiomyopathic hamsters, the mRNA expressions for type I and type III collagen and fibronectin all increased with aging; however, the fibronectin expression in the Bio 14.6 strains increased more at 22 weeks of age than at 42 weeks of age. The left ventricular MMP-1, MMP-2 and MMP-9 activities in Bio 53.58 strains increased with aging. However, in the Bio 14.6 strains, although MMP-1 activities increased with aging, MMP-2 and MMP-9 activities decreased at 42 weeks of age in comparison to those at 22 weeks of age. Thus, the MMP activation differed between two cardiomyopathic models at the stage of heart failure, although the collagen synthesis was elevated in both models. In conclusion, it would seem that the relative balance between the synthesis and the removal of collagen may contribute to the changes in the left ventricular geometry in two different types of cardiomyopathy.


Subject(s)
Aging/physiology , Cardiomyopathy, Dilated/physiopathology , Cardiomyopathy, Hypertrophic/physiopathology , Collagen/genetics , Extracellular Matrix/physiology , Heart/physiopathology , Animals , Body Weight , Cardiomyopathy, Dilated/genetics , Cardiomyopathy, Hypertrophic/genetics , Collagen/metabolism , Cricetinae , Fibronectins/genetics , Heart/growth & development , Mesocricetus , Organ Size , RNA, Messenger/genetics , Species Specificity , Transcription, Genetic
3.
Jpn Circ J ; 60(1): 50-61, 1996 Jan.
Article in English | MEDLINE | ID: mdl-8648884

ABSTRACT

The hereditary cardiomyopathic strain of Syrian hamster has been extensively studied as a model of cardiomyopathy of heart failure. We attempted to determine whether an angiotensin converting enzyme (ACE) inhibitor, enalapril, prevents the increase in extracellular collagen matrix which connects the myocytes in cardiomyopathy. Enalapril was administered at an average dosage of 10 mg/kg per day to 10- to 20-week-old hamsters with hypertrophic (Bio 14.6) and dilated (Bio 53.58) cardiomyopathy, as well as to control Syrian hamsters (F1 beta). Collagen concentration estimated by hydroxyproline concentration and the collagen type III:I ratio significantly increased in the hearts of the Bio 14.6 and Bio 53.58 strains at 20 and 40 weeks of age as, compared with those in age-matched F1 beta hamsters. When Bio 14.6 hamsters were given enalapril for 10 weeks from 10 to 20 weeks of age, the collagen concentration, the collagen type III:I ratio and type III collagen mRNA expression were significantly decreased, compared with those in untreated animals of the same strain. After the administration of enalapril, scanning electron microscopic examination also revealed a decrease in fibrillar collagen accumulation in the interstitium and the network surrounding the cardiac myocytes. These prophylactic effects were not observed in the Bio 53.58 strain. These results indicate that the administration of ACE inhibitor prevents type III collagen production in the Bio 14.6 strain but not in the Bio 53.58 strain of Syrian hamster.


Subject(s)
Angiotensin-Converting Enzyme Inhibitors/pharmacology , Cardiomyopathies/metabolism , Collagen/metabolism , Enalapril/pharmacology , Animals , Cricetinae , Disease Models, Animal , Histocytochemistry , Male , Mesocricetus , Myocardium/metabolism , Myocardium/pathology , RNA/analysis
4.
Am Heart J ; 125(5 Pt 1): 1311-5, 1993 May.
Article in English | MEDLINE | ID: mdl-8386904

ABSTRACT

We investigated the effect of the beta 1-selective blocker metoprolol on the beta-adrenergic receptor density of circulating lymphocytes in patients with dilated cardiomyopathy. Nine men in New York Heart Association functional classes II (six patients) and III were given metoprolol for 6 months (mean dose 45.6 +/- 18.1 mg). Their cardiac function was assessed by echocardiography. Although there was no difference in the heart rate or pressure rate products, the end-systolic and end-diastolic dimensions significantly decreased in six patients after metoprolol treatment. The ejection fraction, fractional shortening, and mean left ventricular circumferential shortening were significantly increased after the treatment. beta-Adrenoceptor densities of lymphocytes, examined by iodine 125-labeled iodocyanopindolol, were reduced in patients at entry but recovered to normal levels after the metoprolol treatment. The dissociation constants did not differ at any stage of the disease. The relationship between beta-adrenoceptor densities in lymphocytes and echocardiographic parameters showed a positive correlation with the plasma norepinephrine concentration. This study thus provides evidence that long-term metoprolol therapy for dilated cardiomyopathy is associated with beta-receptor up-regulation, and the restoration of myocardial beta-receptor density may be associated with the improved cardiac function as determined by echocardiography.


Subject(s)
Cardiomyopathy, Dilated/drug therapy , Lymphocytes/drug effects , Metoprolol/therapeutic use , Receptors, Adrenergic, beta/drug effects , Adult , Aged , Cardiomyopathy, Dilated/blood , Cardiomyopathy, Dilated/diagnostic imaging , Case-Control Studies , Echocardiography , Epinephrine/blood , Humans , Male , Metoprolol/pharmacology , Middle Aged , Norepinephrine/blood , Treatment Outcome , Up-Regulation/drug effects , Ventricular Function, Left/drug effects
5.
Mol Cell Biochem ; 119(1-2): 23-8, 1993 Feb 17.
Article in English | MEDLINE | ID: mdl-8384300

ABSTRACT

Cardiac hypertrophy in rats was produced by aortic banding for 6 weeks and regression of hypertrophy in these experimental animals was induced by administration of angiotensin converting enzyme inhibitor, enalapril (10 mg/kg/day) for 6 weeks. The left ventricular muscle mass and systolic pressure were decrease upon treating the hypertrophied rats with enalapril. This drug also decreased the number of alpha 1-adrenoceptors in hypertrophied myocardium without any changes in beta-adrenoceptors. The regression of cardiac hypertrophy in spontaneously hypertensive rats by enalapril for 10 weeks was not associated with any alterations in alpha 1-adrenoceptors in hypertrophied myocardium, but was decreased in beta-adrenoceptors. Effects of enalapril on extracellular matrix in the myocardium was also observed in regression of hypertrophy in which the type III collagen mRNA expression and collagen contents were reduced in comparison with those of hypertrophied myocardium. These results indicate that regression of cardiac hypertrophy is not always associated with a decrease in the number of alpha 1-adrenergic receptors and that the beneficial effects of enalapril in the hypertrophied heart in aortic banding animals may be of some specific nature.


Subject(s)
Cardiomyopathy, Hypertrophic/drug therapy , Collagen/metabolism , Enalapril/pharmacology , Extracellular Matrix/drug effects , Receptors, Adrenergic, alpha/metabolism , Receptors, Adrenergic, beta/metabolism , Animals , Disease Models, Animal , Down-Regulation , Gene Expression Regulation/drug effects , Male , Rats , Rats, Inbred SHR , Rats, Inbred WKY
SELECTION OF CITATIONS
SEARCH DETAIL
...